ALSO NOTED: Qiagen acquires artus; Centocor gains priority review; Inverness buying diagnostic assets; and much more...

> Qiagen has acquired Germany's artus, which develops detection systems, for $39 million. Story

> The FDA has granted a priority review to Centocor's Remicade for ulcerative colitis. Release

> Inverness Medical is buying diagnostic assets from Abbott for $56.5 million. Release

> USA Today examines the current push to regulate drug marketing in America. Story

> The FDA has concurred with Spectrum Pharmaceuticals IND for SPI-153 and plans a Phase I/II clinical trial for prostate cancer. Release

> India's Ranbaxy has received a tentative nod from the FDA for a new HIV drug. Story

And Finally... A new study suggests that doctors are simply not prescribing cholesterol-lowering statins as frequently as needed. Story

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.